NCT05466890View on ClinicalTrials.gov

Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 15, 2022

Primary Completion Date

February 10, 2025

Study Completion Date

March 31, 2025

Conditions
Ulcerative ColitisUlcerative Colitis AcuteUlcerativeUlcerative Colitis Flare
Interventions
DRUG

PL8177 Placebo

Approximately 1/4 of randomized patients will receive matching placebo as means of comparison to active treatment PL8177.

DRUG

PL8177

Approximately 3/4 of randomized patients will receive active PL8177.

Trial Locations (14)

10065

Weill Cornell Medicine - Jill Roberts Center for Inflammatory Bowel Disease, New York

32806

Orlando Health, Inc., Orlando

33067

Advanced Research LLC, Coral Springs

34741

IHS Health Research/Gastro Health, Kissimmee

67226

Kansas Gastroenterology, Wichita

70503

Gastroenterology Clinic of Acadiana, Lafayette

71201

Delta Research Partners, Monroe

85712

Del Sol Research Management, LLC, Tucson

91356

Valiance Clinical Research, Tarzana

93534

Gastro Care Institute, Lancaster

07631

Allied Health Clinical Research Organization, LLC - Englewood, Englewood

07728

Allied Digestive Health LLC, Freehold

08527

Allied Health Clinical Research Organization, LLC, Jackson

15213-2582

UPMC Presbyterian, Pittsburgh

Sponsors
All Listed Sponsors
lead

Palatin Technologies, Inc

INDUSTRY